Supramolecular Assembled Programmable Nanomedicine As In Situ Cancer Vaccine for Cancer Immunotherapy

Supramolecular Assembled Programmable Nanomedicine As In Situ Cancer Vaccine for Cancer Immunotherapy

© 2021 Wiley-VCH GmbH.

Détails bibliographiques
Publié dans:Advanced materials (Deerfield Beach, Fla.). - 1998. - 33(2021), 7 vom: 12. Feb., Seite e2007293
Auteur principal: Zhang, Yu (Auteur)
Autres auteurs: Ma, Sheng, Liu, Xinming, Xu, Yudi, Zhao, Jiayu, Si, Xinghui, Li, Hongxiang, Huang, Zichao, Wang, Zhenxin, Tang, Zhaohui, Song, Wantong, Chen, Xuesi
Format: Article en ligne
Langue:English
Publié: 2021
Accès à la collection:Advanced materials (Deerfield Beach, Fla.)
Sujets:Journal Article cancer vaccines immunotherapy nanomedicine programmable nanomedicine supramolecular assembly Antibodies, Monoclonal, Humanized Antineoplastic Agents Cancer Vaccines Dendrimers plus... Interleukin-6 PAMAM Starburst Tumor Necrosis Factor-alpha beta-Cyclodextrins Polyethylene Glycols 3WJQ0SDW1A atezolizumab 52CMI0WC3Y betadex JV039JZZ3A
LEADER 01000caa a22002652c 4500
001 NLM320112713
003 DE-627
005 20250228183332.0
007 cr uuu---uuuuu
008 231225s2021 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.202007293  |2 doi 
028 5 2 |a pubmed25n1066.xml 
035 |a (DE-627)NLM320112713 
035 |a (NLM)33448050 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Zhang, Yu  |e verfasserin  |4 aut 
245 1 0 |a Supramolecular Assembled Programmable Nanomedicine As In Situ Cancer Vaccine for Cancer Immunotherapy 
264 1 |c 2021 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 14.10.2021 
500 |a Date Revised 14.10.2021 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2021 Wiley-VCH GmbH. 
520 |a Using nanotechnology for improving the immunotherapy efficiency represents a major research interest in recent years. However, there are paradoxes and obstacles in using a single nanoparticle to fulfill all the requirements in the complicated immune activation processes. Herein, a supramolecular assembled programmable immune activation nanomedicine (PIAN) for sequentially finishing multiple steps after intravenous injection and eliciting robust antitumor immunity in situ is reported. The programmable nanomedicine is constructed by supramolecular assembly via host-guest interactions between poly-[(N-2-hydroxyethyl)-aspartamide]-Pt(IV)/β-cyclodextrin (PPCD), CpG/polyamidoamine-thioketal-adamantane (CpG/PAMAM-TK-Ad), and methoxy poly(ethylene glycol)-thioketal-adamantane (mPEG-TK-Ad). After intravenous injection and accumulation at the tumor site, the high level of reactive oxygen species in the tumor microenvironment promotes PIAN dissociation and the release of PPCD (mediating tumor cell killing and antigen release) and CpG/PAMAM (mediating antigen capturing and transferring to the tumor-draining lymph nodes). This results in antigen-presenting cell activation, antigen presentation, and robust antitumor immune responses. In combination with anti-PD-L1 antibody, the PIAN cures 40% of mice in a colorectal cancer model. This PIAN provides a new framework for designing programmable nanomedicine as in situ cancer vaccine for cancer immunotherapy 
650 4 |a Journal Article 
650 4 |a cancer vaccines 
650 4 |a immunotherapy 
650 4 |a nanomedicine 
650 4 |a programmable nanomedicine 
650 4 |a supramolecular assembly 
650 7 |a Antibodies, Monoclonal, Humanized  |2 NLM 
650 7 |a Antineoplastic Agents  |2 NLM 
650 7 |a Cancer Vaccines  |2 NLM 
650 7 |a Dendrimers  |2 NLM 
650 7 |a Interleukin-6  |2 NLM 
650 7 |a PAMAM Starburst  |2 NLM 
650 7 |a Tumor Necrosis Factor-alpha  |2 NLM 
650 7 |a beta-Cyclodextrins  |2 NLM 
650 7 |a Polyethylene Glycols  |2 NLM 
650 7 |a 3WJQ0SDW1A  |2 NLM 
650 7 |a atezolizumab  |2 NLM 
650 7 |a 52CMI0WC3Y  |2 NLM 
650 7 |a betadex  |2 NLM 
650 7 |a JV039JZZ3A  |2 NLM 
700 1 |a Ma, Sheng  |e verfasserin  |4 aut 
700 1 |a Liu, Xinming  |e verfasserin  |4 aut 
700 1 |a Xu, Yudi  |e verfasserin  |4 aut 
700 1 |a Zhao, Jiayu  |e verfasserin  |4 aut 
700 1 |a Si, Xinghui  |e verfasserin  |4 aut 
700 1 |a Li, Hongxiang  |e verfasserin  |4 aut 
700 1 |a Huang, Zichao  |e verfasserin  |4 aut 
700 1 |a Wang, Zhenxin  |e verfasserin  |4 aut 
700 1 |a Tang, Zhaohui  |e verfasserin  |4 aut 
700 1 |a Song, Wantong  |e verfasserin  |4 aut 
700 1 |a Chen, Xuesi  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 33(2021), 7 vom: 12. Feb., Seite e2007293  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnas 
773 1 8 |g volume:33  |g year:2021  |g number:7  |g day:12  |g month:02  |g pages:e2007293 
856 4 0 |u http://dx.doi.org/10.1002/adma.202007293  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 33  |j 2021  |e 7  |b 12  |c 02  |h e2007293